Tag: GlobeNewswire

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading provider of commerce media solutions, today announced that it will report its financial results for the quarter ended September 30, 2026, after the close of the U.S. financial markets on November 12, 2026. Fluent will host a conference call at 4:30 p.m. ET on the same day to discuss the results.

The conference call can be accessed by phone after registering online at Fluent Conference Call or via audio at Audio Registration. The call and accompanying slide presentation will also be webcast simultaneously on the Fluent website on the Investor Relations Page. Please log in at least 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be required. Following the call, a recorded replay of the webcast will be available for one year on Fluent’s Investor Relations Page.

About Fluent, Inc.
Fluent, Inc. (NASDAQ: FLNT) is a commerce media solutions provider connecting top-tier brands with highly engaged consumers. Leveraging exclusive ad inventory, robust first-party data, and proprietary machine learning, Fluent unlocks additional revenue streams for partners and empowers advertisers to acquire their most valuable customers at scale. Founded in 2010, Fluent uses its deep expertise in performance marketing to drive monetization and increase engagement at key touchpoints across the customer journey. For more insights, visit http://www.fluentco.com/.

Contact Information:
Investor Relations
Fluent, Inc.
InvestorRelations@fluentco.com

Company delivers technical data reports on the development of new AI datasets to detect foreign object debris/damage on U.S. Air Force and civilian airfields

AVENTURA, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) — Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a developer of artificial intelligence (AI)-enabled defense, security, and situational awareness solutions, today announced that it has successfully completed all research milestones under the previously announced Phase I Small Business Innovation Research (SBIR) contract awarded to the Company by AFWERX.

In July, the Company was awarded a Phase I SBIR focused on the development of a new AI dataset using images of Foreign Object Debris/Damage (FOD) that are commonly encountered on both U.S. Air Force (USAF) and civilian airfields to address the most pressing challenges in the Department of the Air Force (DAF). Under the SBIR, Safe Pro demonstrated its SpotlightAI™ AI-powered computer vision technology for small object detection, collected and analyzed high resolution imagery of FOD, and prepared technical project reports. Subject to review and determination by AFWERX, the Company intends to pursue additional SBIR-funded development contracts.

“We wish to thank AFWERX for their collaboration on this project as we work to further demonstrate the significant value and impact that our patented AI-powered computer vision software technology can have in both defense and civilian applications,” said Dan Erdberg, Chairman and CEO of Safe Pro Group Inc.

The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small businesses and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded.

AFWERX is the innovation arm of the Department of the Air Force (DAF) and a directorate within the Air Force Research Laboratory (AFRL). The mission of AFWERX’s SBIR program is to fund emerging technologies to deliver Air Force and Space Force capabilities and broaden access to disruptive innovation.

The development of AI datasets for use in U.S. Air Force airfield operations could significantly expand the applicability of the Company’s proprietary computer vision technology designed to rapidly detect and identify small objects beyond use in battlefield and post-conflict zone land reclamation and rebuilding missions. This AFWERX SBIR award follows recent interest in this capability expressed by the U.S. Army which has invited the Company to provide operational support to soldiers during an upcoming airfield exercise.

Powered by Safe Pro’s patented SPAI Ground Truth software, the Company’s technology uses AI and machine learning algorithms trained on one of the world’s largest real-world drone-based imagery datasets to instantly detect small, hard-to-find threats such as landmines, cluster munitions, UXO, and ambush drones. The platform can identify explosive threats and objects of interest across large-scale, high-risk environments, creating a novel and scalable approach to situational awareness on the battlefield.

For information about Safe Pro Group, its subsidiaries, and technologies, please visit https://safeprogroup.com and connect with us on LinkedIn, Facebook, and X.

The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government.

About Safe Pro Group Inc.
Safe Pro Group Inc. (Nasdaq: SPAI) is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPAI Ground Truth, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. The Company is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing and mapping, leveraging commercially available off-the-shelf drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosive threats, providing a safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform targets multiple markets, including commercial, government, law enforcement, and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear, and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency. For more information on Safe Pro Group Inc., please visit https://safeprogroup.com.

About AFWERX
AFWERX, the innovation arm of the Department of the Air Force and a division within the Air Force Research Laboratory, partners with small businesses, startups and nontraditional vendors to address challenges facing Airmen and Guardians. Headquartered at Wright-Patterson Air Force Base, Ohio, AFWERX strengthens the defense industrial base by expanding access to innovators, building partnerships and accelerating the transition of critical technologies to operational capability. In fiscal year 2025, AFWERX awarded more than 1,000 contracts totaling $1.37 billion and achieved 438 Phase III transitions valued at $8.1 billion. For more information, visit afwerx.com.

Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements relate to future events, future expectations, plans, and prospects. Forward-looking statements in this press release include, without limitation, statements regarding its ability to create new AI models for use in airfield damage assessment and recovery operations and the ability to license its software and the acceptance and continued use of its solutions by potential government, military, and humanitarian organizations, market size projections for unmanned ground vehicles, and the Company’s future business plans and expectations. Although Safe Pro Group believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Safe Pro Group has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “seek,” “target,” “forecast,” “continue,” “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth under Item 1A in the Company’s most recently filed Form 10-K and updated from time to time in the Company’s Form 10-Q filings and in other filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. Any forward-looking statements contained in this press release speak only as of its date. Safe Pro Group undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

Media Relations for Safe Pro Group Inc.:
media@safeprogroup.com

Investor Contact:
Ankit Hira, Managing Director
Solebury Strategic Communications for Safe Pro Group Inc.
spai@soleburystrat.com

SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — H2O America (NASDAQ: HTO) (the “Company”) announced today that it has commenced an underwritten public offering of 6.5 million equity units (the “Offering”), subject to market and other conditions. Each equity unit will be issued in a stated amount of $50 ($325 million aggregate stated amount) and will initially be in the form of a corporate unit consisting of a contract to purchase the Company’s common stock in the future (the “purchase contract”) and a 1/20 undivided beneficial ownership interest in $1,000 principal amount of the Company’s remarketable senior notes due 2031. Pursuant to the terms of the equity units, we expect to issue shares of the Company’s common stock to holders on or about November 1, 2029. Before the issuance of the Company’s common stock upon settlement of the purchase contracts, the purchase contracts will be reflected in the Company’s diluted earnings per share calculations using the treasury stock method.

In connection with the Offering, the Company expects to grant the underwriters an option to purchase up to an additional 975,000 corporate units ($48.75 million additional aggregate stated amount), solely for the purpose of covering over-allotments, within the 13-day period beginning on the day the Company first issues the corporate units.

The Company intends to apply to list the corporate units on the Nasdaq Global Select Market and expects trading to commence within 30 days of the date of initial issuance (subject to listing approval).

The Company intends to use the net proceeds of the Offering for general corporate purposes, which may include acquisitions, capital expenditures or debt repayment, in line with our previously communicated capital plans, and to satisfy a portion of our future equity needs to refinance a portion of our debt maturing in 2029.

Wells Fargo Securities and J.P. Morgan are acting as joint book-running managers and as representatives of the underwriters for the Offering.

The Offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”). The Offering is being made only by means of a prospectus supplement, including the accompanying base prospectus. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus, the registration statement, and the other documents that the Company has filed with the SEC for more complete information about the Company and the Offering. Copies of the preliminary prospectus supplement and the final prospectus supplement, when available, may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov or from Wells Fargo Securities, LLC, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, Attention: WFS Customer Service, toll-free at 1-800-645-3751 or by email at WFScustomerservice@wellsfargo.com or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com.

About H2O America

H2O America is among the largest investor-owned pure-play water and wastewater utilities in the United States, providing life-sustaining and high-quality water service to over 1.7 million people. H2O America includes the following locally led and operated water utilities – San Jose Water Company in California, The Connecticut Water Company in Connecticut, The Maine Water Company in Maine, and SJWTX, Inc. (dba The Texas Water Company) in Texas, including Quadvest’s operations.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements relating to the proposed Offering and expected use of net proceeds, which statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Some of these forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “estimates,” “anticipates,” “intends,” “seeks,” “plans,” “projects,” “may,” “should,” “will,” “approximately,” “strategy,” or the negative of those words or other comparable terminology. These forward-looking statements are only predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements.

The accuracy of such statements is subject to a number of risks, uncertainties and assumptions including, but not limited to, the following factors: (1) the risks associated with the Quadvest and Cibolo Valley transactions, including, the risk of the proposed Cibolo Valley transaction not closing on the anticipated timeline, or at all, and the ability to successfully integrate Quadvest’s and Cibolo Valley’s operations and realize the projected financial and other benefits of the proposed transactions; (2) the effect of water, utility, environmental and other governmental policies and regulations, including regulatory actions concerning rates, authorized return on equity, authorized capital structures, capital expenditures, PFAS and other decisions; (3) changes in demand for water and other services; (4) unanticipated weather conditions and changes in seasonality including those affecting water supply and customer usage; (5) the effect of the impact of climate change; (6) unexpected costs, charges or expenses; (7) our ability to successfully evaluate investments in new business and growth initiatives; (8) contamination of our water supplies and damage or failure of our water equipment and infrastructure; (9) the risk of work stoppages, strikes and other labor-related actions; (10) catastrophic events such as fires, earthquakes, explosions, floods, ice storms, tornadoes, hurricanes, terrorist acts, physical attacks, cyber-attacks, epidemic, or similar occurrences; (11) changes in general economic, political, legislative, business and financial market conditions; (12) the ability to obtain financing on favorable terms, which can be affected by various factors, including credit ratings, changes in interest rates, compliance with regulatory requirements, compliance with the terms and conditions of our outstanding indebtedness, and general market and economic conditions; and (13) legislative and general market and economic developments. The risks, uncertainties and other factors may cause the actual results, performance or achievements of H2O America to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Other factors that may cause actual results, performance or achievements to materially differ are described in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

H2O America Contacts:

Ann P. Kelly
Chief Financial Officer and Treasurer
(408) 385-4752
Ann.Kelly@H2O-America.com

Jonathan G. Reeder
Senior Director of Treasury & Investor Relations
(475) 414-1034
InvestorRelations@H2O-America.com

PETAH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that members of its management team will attend the following conference:

Deutsche Bank Global Space and Defense Tech Summit – November 18th, 2026

• Format: one-on-ones, group meetings
• Location: NYC
• Participants: Adi Sfadia, Chief Executive Officer & Gil Benyamini, Chief Financial Officer

About Gilat

Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT) is a leading global provider of satellite-based broadband communications. With over 35 years of experience, we develop and deliver deep technology solutions for satellite, ground, and new space connectivity, offering next-generation solutions and services for critical connectivity across commercial and defense applications. We believe in the right of all people to be connected and are united in our resolution to provide communication solutions to all reaches of the world.

Together with our wholly owned subsidiaries Gilat Wavestream, Gilat DataPath, and Gilat Stellar Blu, we offer integrated, high-value solutions supporting multi-orbit constellations, Very High Throughput Satellites (VHTS), and Software-Defined Satellites (SDS) via our Commercial and Defense Divisions. Our comprehensive portfolio is comprised of a software-defined platform and modems, high-performance satellite terminals, advanced Satellite On-the-Move (SOTM) antennas and ESAs, highly efficient, high-power Solid State Power Amplifiers (SSPA) and Block Upconverters (BUC) and includes integrated ground systems for commercial and defense markets, field services, network management software, and cybersecurity services.

Gilat’s products and tailored solutions support multiple applications including government and defense, IFC and mobility, cellular backhaul, enterprise, aerospace and critical infrastructure clients all while meeting the most stringent service level requirements. For more information, please visit: http://www.gilat.com

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Gilat to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, changes in general economic and business conditions, inability to maintain market acceptance to Gilat’s products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for Gilat’s products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company’s proprietary technology and risks associated with Gilat’s international operations and its location in Israel. For additional information regarding these and other risks and uncertainties associated with Gilat’s business, reference is made to Gilat’s reports filed from time to time with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.

Contact:

Gilat Satellite Networks
PublicRelations@gilat.com

Investor Relations Contact (U.S.)
Alliance Advisors Investor Relations
GilatIR@allianceadvisors.com 

During the Investor Conference Webinar by Tomas Varenbergas, acting CEO, Paulius Daukša, acting CFO, Indrė Genytė-Pikčienė, Chief Economist, and Tautvydas Mėdžius, Chief of Staff, introduced the Bank’s financial results for 9M 2026 and recent developments and answered the participant questions afterwards.

The recording of it can be found on Artea YouTube channel there.

Presentation and the recording of webinar are also posted on the Bank’s website www.artea.lt/en/investors

Artea Bank thanks all participants.

If you would like to receive Artea Bank news for investors directly to your inbox, subscribe to our newsletter.

Additional information:
Arnas Šukys,
Head of Investor Relations
arnas.sukys@artea.lt; +370 610 44447

ROSEMONT, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) — Midera Food Processing, Inc. (NASDAQ: MFP) (“Midera” or the “Company”), will release fiscal third quarter 2026 earnings results on Tuesday, November 17, 2026, before the market open.

Management will host a conference call to discuss its financial results on November 17, 2026, at approximately 9:00 AM CT (10:00 AM ET). A live webcast of the conference call can be accessed by visiting the Company’s Investor Relations website at investors.midera.com.

A replay of the webcast will be available following the conference call at investors.midera.com.

About Midera Food Processing
Midera Food Processing provides food processing equipment and automation solutions for industrial protein, bakery, and snack producers, delivering total line solutions from preparation and thermal processing through packaging. With a portfolio of 30+ industry-leading brands reaching customers across six continents, Midera helps food processors produce safer, more consistent products while improving efficiency and reducing waste at scale. Headquartered in Rosemont, Illinois, the company employs approximately 2,800 people worldwide. For more information about Midera, please visit www.midera.com.

Contact:
investors@midera.com

New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families

STOUGHTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, and Boston Legacy FC, Boston’s professional women’s soccer club, today announced an expanded, multi-year partnership to deepen their commitment to Boston communities and create more opportunities for neurodivergent children and families, including those living with attention-deficit/hyperactivity disorder (ADHD).

Building on their existing Collegium Sensory Room partnership, Collegium and Boston Legacy FC will help youth soccer coaches better support neurodivergent children and bring families, experts and community leaders together through an annual Collegium Summit: Sports for All. The expanded partnership extends their work beyond matchday into communities across Massachusetts and deepens Collegium’s local commitment ahead of its headquarters move to Boston in early 2027.

ADHD is common among school-age children. The Centers for Disease Control and Prevention (CDC) reports, based on 2022 National Survey of Children’s Health data, that 10.5% of U.S. children aged 3–17, or 6.5 million children, have ever received an ADHD diagnosis.¹ Published research indicates that children with ADHD may participate in youth sports less often and less successfully, and that youth sport coaches have reported less positive attitudes about including these children on their teams.² The partnership’s new programs will help coaches better support children with ADHD and bring families and experts together to explore ways to make sports more accessible and inclusive.

“As a leader in ADHD, Collegium recognizes the importance of addressing every part of life that matters to those living with ADHD and their families, from the classroom to the soccer pitch to the dinner table,” said Vikram Karnani, President and Chief Executive Officer, Collegium Pharmaceutical. “We believe healthier people and stronger communities go hand in hand. Our partnership with Boston Legacy FC puts that belief into action by helping children participate in sports, build friendships and feel included, and by giving coaches practical training to support them. Massachusetts is where we begin, and we will keep growing this effort for families everywhere.”

The expanded partnership includes:

• Soccer Coaching Certification Initiative: Boston Legacy FC and Collegium will launch a coaching certification initiative to equip coaches to better support kids with ADHD and other neurodevelopmental conditions. Coaches will have the opportunity to earn a certification recognizing their completion of the training. The initiative is planned to launch in Massachusetts in 2027 and continue through 2029, with regional and national expansion envisioned.
• Annual Collegium Summit: Sports for All: Boston Legacy FC will host an annual Collegium Sports for All Summit at its new Performance Center in Brockton, Mass., bringing together patients, caregivers, medical professionals, advocates, athletes and community leaders to discuss accessibility, neurodiversity and participation in sports. The gathering will provide a forum to share experiences and explore ways to better support neurodivergent children and families.
• Continued Sensory Inclusion: The partnership will continue to support the Collegium Sensory Room, which provides a quieter space for fans who need a break from the noise, crowds and visual stimulation of matchday.

The partnership also includes an increased presence for Collegium as an Official Partner of Boston Legacy FC. Collegium’s logo will appear on the upper back of all Boston Legacy FC game kits, including the primary, secondary and goalkeeper kits, at every home and away match. Collegium will also have permanent signage on the press box at White Stadium, joining the club’s other long-term partners.

“We’re proud to expand our partnership with Collegium and build on our shared commitment to making soccer more inclusive and accessible. From featuring Collegium on our kits to expanding our community initiatives, this partnership allows us to extend our impact beyond the pitch and create meaningful opportunities for children and families to feel welcomed, supported and connected through sport,” said Amina Bulman, Chief Revenue Officer of Boston Legacy FC. “We’re excited about what we can achieve together and the meaningful, lasting impact we can make in our communities.”

The expanded partnership builds on community programming already underway. On Oct. 24, 2026, Collegium presented an adaptive soccer clinic in collaboration with Boston Legacy FC, UMass Shriver Center, and Mass Youth Soccer. The clinic, held at SBLI Fields at Progin Park, paired children with volunteer buddies for a supportive soccer experience, providing an early example of the inclusive community programming.

ABOUT COLLEGIUM PHARMACEUTICAL

Collegium Pharmaceutical is a dynamic biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system (CNS) and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

With a portfolio of differentiated ADHD medications and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.

For more information, please visit collegiumpharma.com or find us on LinkedIn.

ABOUT BOSTON LEGACY FC

Boston Legacy FC is the 15^th team in the National Women’s Soccer League (NWSL), currently playing its inaugural season at Gillette Stadium and Centreville Bank Stadium. Founded and led by women, the club is committed to creating a home for the greatest female athletes of our time, building upon the supercharged legacy of Boston’s historic sports teams, cultivating a community of fans with impact at its core, and forging new connections across our city through sport. For more information, please visit bostonlegacyfc.com or its social media platforms – LinkedIn, Instagram, Twitter (X), Tiktok, Bluesky, Facebook

MEDIA CONTACTS

Boston Legacy FC Media Contact
Sara Rooke
Director of Communications, Boston Legacy FC
srooke@bostonlegacyfc.com
617-872-9453

Collegium Media Contact
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com

REFERENCES

1. Danielson ML, et al. ADHD Prevalence Among U.S. Children and Adolescents in 2022. Journal of Clinical Child & Adolescent Psychology, 2024;53(3):343–360. https://stacks.cdc.gov/view/cdc/160350

2. O’Connor BC, Fabiano GA, et al. Effects of a Summer Treatment Program on Functional Sports Outcomes in Young Children with ADHD. PubMed Central. Cites Beyer et al., 2008, International Journal of Sports Science & Coaching, 3, 555–563, for coach attitudes. https://pmc.ncbi.nlm.nih.gov/articles/PMC4399495

Photos accompanying this announcement are available at: 
https://www.globenewswire.com/NewsRoom/AttachmentNg/1a410b80-fea3-4a0b-9b4a-89ea849a75d7
https://www.globenewswire.com/NewsRoom/AttachmentNg/518a5af8-5b64-40e0-af62-774efda33cdf
https://www.globenewswire.com/NewsRoom/AttachmentNg/36916660-abce-4652-9943-64a9f9d07338
https://www.globenewswire.com/NewsRoom/AttachmentNg/81302822-75e7-474b-84bd-782639b75130
https://www.globenewswire.com/NewsRoom/AttachmentNg/0ff18e8f-8874-49cf-a0ae-0d4f99c9ed25

Seven-Figure Annual Minimum Commitment Builds on a Relationship that Started with an Image of the International Space Station in 2020 and Has Grown More than 40-Fold

HEO used Satellogic’s NewSat 46, from a distance of 17.22 km with an image resolution of 3 cm/px, to capture this image of AST’s BlueWalker 3 satellite on October 24, 2026.

ORLANDO, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), the infrastructure company for Persistent Global Intelligence (PGI), and HEO, a space intelligence company that images and analyzes objects in orbit on demand, today announced a three-year agreement under which Satellogic will provide HEO access to its high-resolution constellation to conduct Non-Earth Imaging (NEI) and generate insights, supporting space domain awareness globally. The recently signed agreement runs through 2029 and includes a seven-figure minimum annual commitment for each of its three years.

The agreement, announced today at Economist Enterprise’s Space Economy Summit, extends a collaboration that dates back to September 2020, when HEO approached Satellogic about imaging objects in orbit. The companies began with a small, co-funded engineering effort to adapt Satellogic’s Earth observation satellites for non-Earth imaging, and the first capture was the International Space Station. Satellogic is HEO’s longest-standing Earth observation constellation partner. Successful captures using Satellogic’s fleet have grown from about 30 in 2021, the first full year of service, to over 1,600 under the most recent agreement in the last year.

“HEO came to us in 2020 with a question few people in our industry had asked yet: what can an Earth observation satellite see if you point it at what’s in orbit?” said Emiliano Kargieman, CEO and Co-Founder of Satellogic. “Our first project was a picture of the International Space Station. Six years and well over a thousand captures per year later, HEO has taken the capability and become a leader in NEI and space domain awareness.”

HEO has access to more satellites through Satellogic than through any other provider in its network. That means more revisit opportunities for each target, more viewing angles, and faster time to first image. The agreement covers Satellogic’s NewSat Mark IV, Mark V and Mark VI satellites, including its newest inter-satellite link (ISL)-equipped spacecraft.

“Satellogic was one of our earliest partners to back non-Earth imaging, and our partnership has continued to grow through collaboration and innovation ever since,” said Dr. Will Crowe, CEO and Co-Founder of HEO. “Together, we’ve continued to find new ways to adapt their fleet for satellite inspection, improving the quality of imagery and insights available to our customers. Their satellites and our shared innovation give us flexibility as we work to view more objects in space and deliver better data to the government and defense customers whose missions depend on it. The three-year commitment gives us the confidence to keep pushing what’s possible.”

About Satellogic

Founded in 2010, Satellogic (NASDAQ: SATL) builds the infrastructure for Persistent Global Intelligence (PGI): continuous, proactive awareness of the places, assets, and activities that matter. The company combines high-cadence satellite collection, best-in-class technology, AI-accelerated workflows, and sovereign-trusted architecture to help customers move from episodic imagery to persistent monitoring programs.

Satellogic serves allied defense and intelligence agencies, civil governments, and commercial markets that need reliable, scalable awareness of change across large portfolios of sites. Customers can begin with discovery, expand into persistent monitoring, and build toward dedicated or sovereign-controlled capacity as their mission requirements grow. To learn more, please visit: https://www.satellogic.com.

About HEO

HEO is building the intelligence layer for space. We image objects in orbit on demand, turning existing satellites into inspection platforms and building our own sensors where coverage gaps remain. Our software automates tasking, capture and analysis, turning imagery into decision-ready intelligence about satellites, debris and other objects in orbit. HEO operates internationally, with offices in Australia, France, Japan, the United Kingdom and the United States. Our goal is to make any image in the Solar System available on Demand. To learn more, please visit: https://www.heospace.com/

About the Economist Enterprise’s 4th annual Space Economy Summit

Economist Enterprise’s 4th annual Space Economy Summit, taking place October 28–29, 2026, at the University of Central Florida in Orlando, convenes senior leaders from government, space, investment and industry. Under the theme “Maximising returns to Earth: the infinite potential of space,” the summit examines how innovation in orbit can deliver measurable commercial and strategic value across the wider economy.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning, among other things, the capabilities, performance, and potential applications of Satellogic’s satellites, constellations, satellite software, and pipeline. Although we believe our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot give any assurance that we either will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions, including risks related to the performance of satellites and software once in orbit and reliance on third parties. Many actual events and circumstances are beyond the control of the Company. Many factors could cause actual future results to differ materially from the forward-looking statements in this press release, including but not limited to the risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 10-K and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Satellogic assumes no obligation and does not intend to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts

Satellogic Investor Relations:
ir@satellogic.com

Satellogic Media Relations:
pr@satellogic.com

HEO:
media@heospace.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c4989eb2-cee3-45fa-90fb-9759da74aa81

Company to report third quarter 2026 financial results on November 5

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the Company’s senior management team will participate in a virtual fireside chat on Friday, November 6, 2026, at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the third quarter ended September 30, 2026, after the market close on Thursday, November 5, 2026.

The live fireside chat can be accessed by clicking here or on the Company’s website at www.vaxart.com.

Investors may submit written questions in advance of the conference call to ir@vaxart.com or through the webcast portal.

A replay of the fireside chat webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com

• Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals
• Poster presentations to include patient perspective about life after lonvo-z treatment
• Intellia to host investor webcast on Thursday, November 12 at 10 a.m. ET

CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced two oral presentations and five poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16 in Phoenix, Arizona. Intellia also announced that it will host an investor webcast on Thursday, November 12, at 8 a.m. MT / 10 a.m. ET to share highlights from the presentations, provide perspectives from HAE key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.

Oral Presentation Details:

• Title: Four-Year Durability/Safety of Lonvoguran Ziclumeran (Lonvo-z) 50 mg in Patients with Hereditary Angioedema
  Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
  Date and Time: Saturday, November 14, 2026, from 4:43 – 4:53 p.m. MT
  Presenter: Danny Cohn, M.D., Ph.D., Associate Professor, Amsterdam University Medical Center, Department of Vascular Medicine, University of Amsterdam; Phase 1/2 and HAELO principal investigator
• Title: Attack-Free and Long-Term Prophylaxis-Free Status Following Treatment with Lonvoguran Ziclumeran in Hereditary Angioedema
  Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
  Date and Time: Saturday, November 14, 2026, from 4:53 – 5:03 p.m. MT
  Presenter: Emel Aygören-Pürsün, M.D., Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University; Phase 1/2 and HAELO principal investigator

Poster Presentation Details:

• Title: Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 3:05 – 3:20 p.m. MT
  Presenter: Marc Riedl, M.D., Professor of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center, University of California San Diego; HAELO principal investigator
• Title: Lived Experiences of Patients Treated with Lonvoguran Ziclumeran, a One-Time CRISPR Treatment for Hereditary Angioedema
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 3:20 – 3:35 p.m. MT
  Presenter: Padmalal Gurugama, MBBS, M.S., M.D., MRCP, FRCPath, Consultant, Clinical Immunology and Allergy, Cambridge University Hospitals NHS Foundation Trust; Phase 1/2 and HAELO principal investigator
• Title: Long-Term Prophylaxis for Hereditary Angioedema: Treatment Use, Patterns, and Gaps in a U.S. Claims Database
  Poster Session: Monitor 18
  Date and Time: Friday, November 13, 2026, from 4:05 – 4:20 p.m. MT
  Presenter: Raffi Tachdjian, M.D., M.P.H., Associate Clinical Professor of Medicine and Pediatrics, Division of Allergy and Clinical Immunology, David Geffen School of Medicine, University of Los Angeles; HAELO principal investigator
• Title: A One-Time Treatment of Lonvoguran Ziclumeran Improves Quality of Life in Patients with Hereditary Angioedema
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 4:35 – 4:50 p.m. MT
  Presenter: William Lumry, M.D., Clinical Professor of Internal Medicine, Allergy and Immunology Division, University of Texas Southwestern Medical School, Medical Director, AARA Research Center; HAELO principal investigator
• Title: Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy, Safety, and Tolerability
  Poster Session: Monitor 16
  Date and Time: Friday, November 13, 2026, from 5:35 – 5:50 p.m. MT
  Presenter: Aleena Banerji, M.D., Professor at Harvard Medical School, Director of Clinical Care, Center for Drug and Vaccine Allergy at Massachusetts General Hospital; HAELO principal investigator

The presentations will be made available on the Scientific Publications & Presentations page of www.intelliatx.com at the start of each respective session.

Intellia Therapeutics Investor Webcast
Intellia will host a live webcast on Thursday, November 12, 2026, at 8 a.m. MT / 10 a.m. ET to review data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE. To join the webcast, visit the Events page of the Investors & Media section of the company’s website at www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 90 days following the call.

About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) Designations by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. In September 2026, the FDA accepted the Biologics License Application (BLA) for lonvo-z and granted Priority Review with a PDUFA target action date of March 10, 2027.

About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Forward-Looking Statements

This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran (“lonvo-z”) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of its biologics license application (“BLA”) for lonvo-z, such as the timing of such review and approval based on the Prescription Drug User Fee Act (“PDUFA”) target action date of March 10, 2027 for the BLA; its belief that lonvo-z could permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting; and its expectations regarding its preparations for and the potential success of the commercial launch of lonvo-z, if approved.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the review and approval of the BLA for lonvo-z and the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its recent quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com